BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 29284153)

  • 1. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
    J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting RET for thyroid cancer therapy.
    Lanzi C; Cassinelli G; Nicolini V; Zunino F
    Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting RET receptor tyrosine kinase activation in cancer.
    Phay JE; Shah MH
    Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.